

DEAV2002/0049 US NP


PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the formula I



wherein

R1, R2 are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO<sub>2</sub>, CN, COOH, CO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy, HO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, phenyl, benzyl, or (C<sub>1</sub>-C<sub>4</sub>)-alkylcarbonyl,

wherein one, more than one or all hydrogens in the alkyl or alkoxy radicals are optionally replaced by fluorine;

SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(CH<sub>2</sub>)<sub>o</sub>-phenyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO-(CH<sub>2</sub>)<sub>o</sub>-phenyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or SO<sub>2</sub>-(CH<sub>2</sub>)<sub>o</sub>-phenyl,

wherein o is 0-6 and wherein the phenyl radical is optionally substituted up to twice, each substituent chosen independently from F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, and NH<sub>2</sub>;

NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acyl, phenyl, or O-(CH<sub>2</sub>)<sub>o</sub>-phenyl,

DEAV2002/0049 US NP

PATENT

wherein o is 0-6 and wherein the phenyl ring is optionally substituted one to 3 times, each substituent chosen independently from F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, and CONH<sub>2</sub>;

A is -CH=CH-CH<sub>2</sub>- or (C<sub>1</sub>-C<sub>4</sub>)-alkanediyl, wherein one or two CH<sub>2</sub> groups are optionally replaced by -(C=O)-, -CH=CH-, -CH(OH)-, -NH-, -CHF-, -CF<sub>2</sub>-, or -O-;

n is a number 2 or 3;

Cycl is a 5- to 6-membered unsaturated ring, wherein 1 carbon atom is optionally replaced by O or S;

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO<sub>2</sub>, CN, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>12</sub>)-alkoxy, HO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or (C<sub>1</sub>-C<sub>6</sub>)-alkoxy-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,

wherein one, more than one or all hydrogens in the alkyl and alkoxy radicals are optionally replaced by fluorine;

SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(CH<sub>2</sub>)<sub>o</sub>-phenyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO-(CH<sub>2</sub>)<sub>o</sub>-phenyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or SO<sub>2</sub>-(CH<sub>2</sub>)<sub>o</sub>-phenyl,

wherein o is 0-6 and wherein the phenyl radical is optionally substituted up to twice, each substituent chosen independently from F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, and NH<sub>2</sub>;

NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acyl, phenyl, (CH<sub>2</sub>)<sub>o</sub>-phenyl, O-(CH<sub>2</sub>)<sub>o</sub>-phenyl,

wherein o is 0-6 and wherein the phenyl ring is optionally substituted one to 3 times, each substituent chosen

DEAV2002/0049 US NP

PATENT

independently from F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>1</sub>-C<sub>3</sub>)-alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, and CONH<sub>2</sub>;

or

R3 and R4 together with the carbon atoms carrying them are a 5- to 7-membered, saturated, partially or completely unsaturated ring Cyc2,

wherein 1 or 2 carbon atoms in the ring are optionally replaced by N, O or S, and

wherein Cyc2 is optionally substituted by (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>5</sub>)-alkenyl, (C<sub>2</sub>-C<sub>5</sub>)-alkynyl,

wherein, in each substituent of Cyc2, one CH<sub>2</sub> group is optionally replaced by O, or substituted by H, F, Cl, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, COO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or OCF<sub>3</sub>; and

R5 is hydrogen;

or a pharmaceutically acceptable salt thereof, solvate, prodrug derivative, ester derivative, polymorphous form, racemate, racemic mixture, pure enantiomer, diastereomer or mixtures thereof.

2. (Previously Presented) The compound of claim 1, wherein A is linked to the thienyl ring in position 2.
3. (Previously Presented) The compound of claim 1, wherein

R1, R2 are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO<sub>2</sub>, CN, COOH, CO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy, HO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, phenyl, benzyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylcarbonyl, or SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein one, more than one or all hydrogens in the alkyl or alkoxy radicals are optionally replaced by fluorine;

## DEAV2002/0049 US NP

## PATENT

R3, R4, R5 are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO<sub>2</sub>, CN, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>12</sub>)-alkoxy, HO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkoxy-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylphenyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxyphenyl, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,

wherein one, more than one or all hydrogens in the alkyl or alkoxy radicals are optionally replaced by fluorine;

or

R3 and R4 together with the carbon atoms carrying them are a 5- to 7-membered, saturated, partially or completely unsaturated ring Cyc2,

wherein 1 or 2 carbon atoms in the ring are optionally replaced by N, O or S, and

wherein Cyc2 is optionally substituted by (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>5</sub>)-alkenyl, or (C<sub>2</sub>-C<sub>5</sub>)-alkynyl,

wherein in each substituent of Cyc2, one CH<sub>2</sub> group is optionally replaced by O, or substituted by H, F, Cl, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, COO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or OCF<sub>3</sub>, and

R5 is hydrogen.

4. (Previously Presented) The compound of claim 1, wherein

R1, R2 are, independently of each other, hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, HO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, F, Cl, CF<sub>3</sub>, OCF<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl-CF<sub>2</sub>-, phenyl, benzyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylcarbonyl, (C<sub>2</sub>-C<sub>4</sub>)-alkenyl, (C<sub>2</sub>-C<sub>4</sub>)-alkynyl, or COO(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R3, R4, R5 are, independently of each other, hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OH, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkoxy, OCF<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COOH, HO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylphenyl, or (C<sub>1</sub>-C<sub>2</sub>)-alkoxyphenyl, or

## DEAV2002/0049 US NP

## PATENT

R3 and R4 together are  $-\text{CH}=\text{CH}-\text{O}-$ ,  $-\text{CH}=\text{CH}-\text{S}-$ ,  $-\text{O}-(\text{CH}_2)_p-\text{O}-$ ,  $-\text{O}-\text{CF}_2-\text{O}-$ , or  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ , wherein  $p = 1$  or  $2$ , and

R5 is hydrogen.

5. (Previously Presented) The compound of claim 1, wherein R2 is hydrogen.

6. (Previously Presented) The compound of claim 1, wherein

R1 is hydrogen,  $\text{CF}_3$ ,  $(\text{C}_1-\text{C}_4)$ -alkyl, or phenyl,

R2 is hydrogen,

A is  $-\text{CH}_2-$ ,  $-\text{C}_2\text{H}_4-$ ,  $-\text{C}_3\text{H}_6-$ ,  $-\text{CH}(\text{OH})-$ ,  $-(\text{C}=\text{O})-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{CH}=\text{CH}-\text{CH}_2-$ ,  $-\text{CO}-\text{CH}_2-\text{CH}_2-$  or  $-\text{CO}-\text{NH}-\text{CH}_2-$ ;

Cyc1 is an a 5- to 6-membered unsaturated ring, wherein 1 carbon atom is optionally replaced by S;

R3, R4, and R5 are, independently of each other, hydrogen, F, Cl, I,  $\text{NO}_2$ , OH, CN,  $(\text{C}_1-\text{C}_6)$ -alkyl,  $(\text{C}_1-\text{C}_8)$ -alkoxy,  $\text{O}-\text{CH}_2$ -phenyl,  $\text{OCF}_3$ ,  $\text{S}-\text{CH}_3$ , or  $\text{COOH}$  or

R3 and R4 together are  $-\text{CH}=\text{CH}-\text{O}-$ ,  $-\text{O}-(\text{CH}_2)_p-\text{O}-$ ,  $-\text{O}-\text{CF}_2-\text{O}-$ ,  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ , wherein  $p = 1$  or  $2$ , and

R5 is hydrogen.

7. (Previously Presented) The compound of claim 1, wherein

A is  $-\text{CH}_2-$  or  $-\text{CH}_2-\text{CH}_2-$ .

8. (Previously Presented) The compound of claim 1, wherein

Cyc1 is phenyl.

DEAV2002/0049 US NP


PATENT

9. (Previously Presented) The compound of claim 1, wherein Cyc1 is thienyl.
10. (Previously Presented) The compound of claim 1, wherein Cyc1 is monosubstituted.
11. (Previously Presented) A medicament comprising at least one compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
12. (Original) A medicament comprising at least one compound as claimed in claim 1 and at least one more blood glucose-lowering active ingredient.
13. (Original) A method for treating type 1 or type 2 diabetes, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1.
14. (Original) A method for lowering blood glucose, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1.
15. (Original) A method for treating type 1 or type 2 diabetes, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1 and at least one other active ingredient, wherein the at least one other active ingredient is effective for lowering blood glucose.
16. (Original) A method for lowering blood glucose, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1 and at least one other active ingredient, wherein the at least one other active ingredient is effective for lowering blood glucose.
17. (Original) A process for producing a medicament comprising at least one compound as claimed in claim 1, comprising:  
mixing the at least one compound as claimed in claim 1 with a pharmaceutically suitable carrier, and



DEAV2002/0049 US NP


PATENT






DEAV2002/0049 US NP

PATENT




DEAV2002/0049 US NP

PATENT



DEAV2002/0049 US NP


PATENT



20. (New) The compound according to claim 19 selected from the group consisting of:

DEAV2002/0049 US NP


PATENT




DEAV2002/0049 US NP

PATENT


20. (New) A compound according to claim 20, wherein the compound is




21. (New) A compound according to claim 20, wherein the compound is



22. (New) A compound according to claim 20, wherein the compound is




23. (New) A compound according to claim 20, wherein the compound is




DEAV2002/0049 US NP

PATENT


24. (New) A compound according to claim 20, wherein the compound is




25. (New) A compound according to claim 20, wherein the compound is



26. (New) A compound according to claim 20, wherein the compound is




27. (New) A compound according to claim 20, wherein the compound is



DEAV2002/0049 US NP

PATENT

28. (New) A compound according to claim 20, wherein the compound is



29. (New) A compound according to claim 20, wherein the compound is

